...
首页> 外文期刊>Perfusion >Is there any difference between blood and crystalloid cardioplegia for myocardial protection during cardiac surgery? A meta-analysis of 5576 patients from 36 randomized trials
【24h】

Is there any difference between blood and crystalloid cardioplegia for myocardial protection during cardiac surgery? A meta-analysis of 5576 patients from 36 randomized trials

机译:心脏手术中血液和结晶性心脏停搏对心肌的保护有什么区别吗?来自36个随机试验的5576名患者的荟萃分析

获取原文
获取原文并翻译 | 示例

摘要

Objective: To compare the efficacy of blood versus crystalloid cardioplegia for myocardial protection in patients undergoing cardiac surgery. Methods: MEDLINE, EMBASE, CENTRAL/CCTR, SciELO, LILACS, Google Scholar and reference lists of relevant articles were searched for clinical studies that reported in-hospital outcomes after blood or crystalloid cardioplegia for myocardial protection during cardiac surgery procedures from 1966 to 2011. The principal summary measures were risk ratio (RR) for blood compared to crystalloid cardioplegia with 95% Confidence Interval (CI) and P values (considered statistically significant when <0.05). The RRs were combined across studies using the DerSimonian-Laird random effects model and fixed effects model using the Mantel-Haenszel model - both models were weighted. The meta-analysis was completed using the software Comprehensive Meta-Analysis version 2 (Biostat Inc., Englewood, New Jersey). Results: Thirty-six studies (randomized trials) were identified and included a total of 5576 patients (2834 for blood and 2742 for crystalloid). There was no significant difference between the blood and crystalloid groups in the risk for death (risk ratio [RR] 0.951, 95% CI 0.598 to 1.514, P=0.828, for both effect models) or myocardial infarction (RR 0.795, 95% CI 0.547 to 1.118, P=0.164, for both effect models) or low cardiac output syndrome (RR 0.765, 95% CI 0.580 to 1.142, P=0.094, for the fixed effect model; RR 0.690, 95% CI 0.480 to 1.042, P=0.072, for the random effect model). It was observed that there was no publication bias or heterogeneity of effects about any outcome. Conclusion: We found evidence that argues against any superiority in terms of hard outcomes between blood or crystalloid cardioplegia for myocardial protection during cardiac surgery.
机译:目的:比较血液和晶体性停跳对心脏手术患者心肌保护的疗效。方法:检索1966年至2011年在心脏外科手术期间进行血液或晶体性心肌麻痹后住院治疗对心肌的保护作用的临床研究,以检索MEDLINE,EMBASE,CENTRAL / CCTR,SciELO,LILACS,Google Scholar和相关文章的参考文献清单以进行临床研究。主要的摘要指标是血液风险比(RR)与具有95%的置信区间(CI)和P值的晶体性心脏停搏(在<0.05时具有统计学意义)。使用DerSimonian-Laird随机效应模型和使用Mantel-Haenszel模型的固定效应模型对整个研究的RR进行合并-两种模型都经过加权。使用软件综合综合分析版本2(新泽西州恩格尔伍德的Biostat Inc.)完成荟萃分析。结果:确定了36项研究(随机试验),包括5576例患者(血液2834例和晶体2742例)。血液和晶体组之间的死亡风险(两种效应模型的风险比[RR] 0.951,95%CI 0.598至1.514,P = 0.828,两者均无显着差异)或心肌梗死(RR 0.795,95%CI)两种效应模型均为0.547至1.118,P = 0.164)或低心排血综合征(固定效应模型为RR 0.765,95%CI 0.580至1.142,P = 0.094; RR 0.690,95%CI 0.480至1.042,P = 0.072(对于随机效果模型)。观察到,对于任何结局都没有发表偏倚或影响的异质性。结论:我们发现证据表明,在心脏手术期间血液或晶体性停跳对硬膜外保护之间的硬性结局方面没有任何优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号